Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2007 Apr;51(4):1191-201.
doi: 10.1128/AAC.01321-06. Epub 2007 Jan 29.

In vitro and in vivo activities of PD 0305970 and PD 0326448, new bacterial gyrase/topoisomerase inhibitors with potent antibacterial activities versus multidrug-resistant gram-positive and fastidious organism groups

Michael D Huband  1 , Michael A Cohen, Margaret Zurack, Debra L Hanna, Laura A Skerlos, Mark C Sulavik, Glenn W Gibson, Jeffrey W Gage, Edmund Ellsworth, Michael A Stier, Stephen J Gracheck
Affiliations

In vitro and in vivo activities of PD 0305970 and PD 0326448, new bacterial gyrase/topoisomerase inhibitors with potent antibacterial activities versus multidrug-resistant gram-positive and fastidious organism groups

Michael D Huband et al. Antimicrob Agents Chemother. 2007 Apr.

Abstract

PD 0305970 and PD 0326448 are new bacterial gyrase and topoisomerase inhibitors (quinazoline-2,4-diones) that possess outstanding in vitro and in vivo activities against a wide spectrum of bacterial species including quinolone- and multidrug-resistant gram-positive and fastidious organism groups. The respective MICs (microg/ml) for PD 0305970 capable of inhibiting>or=90% of bacterial strains tested ranged from 0.125 to 0.5 versus staphylococci, 0.03 to 0.06 versus streptococci, 0.25 to 2 versus enterococci, and 0.25 to 0.5 versus Moraxella catarrhalis, Haemophilus influenzae, Listeria monocytogenes, Legionella pneumophila, and Neisseria spp. PD 0326448 MIC90s were generally twofold higher versus these same organism groups. Comparative quinolone MIC90 values were 4- to 512-fold higher than those of PD 0305970. In testing for frequency of resistance, PD 0305970 and levofloxacin showed low levels of development of spontaneous resistant mutants versus both Staphylococcus aureus and Streptococcus pneumoniae. Unlike quinolones, which target primarily gyrA and parC, analysis of resistant mutants in S. pneumoniae indicates that the likely targets of PD 0305970 are gyrB and parE. PD 0305970 demonstrated rapid bactericidal activity by in vitro time-kill testing versus streptococci. This bactericidal activity carried over to in vivo testing, where PD 0305970 and PD 0326448 displayed outstanding Streptococcus pyogenes 50% protective doses (PD50s) (oral dosing) of 0.7 and 3.6 mg/kg, respectively (ciprofloxacin and levofloxacin PD50s were>100 and 17.7 mg/kg, respectively). PD 0305970 was also potent in a pneumococcal pneumonia mouse infection model (PD50=3.2 mg/kg) and was 22-fold more potent than levofloxacin.

PubMed Disclaimer

Figures

FIG. 1.
FIG. 1.
PD 0305970.
FIG. 2.
FIG. 2.
PD 0326448.
FIG. 3.
FIG. 3.
PD 0305970 (MIC = 0.008 μg/ml) versus S. pneumoniae SVI.
FIG. 4.
FIG. 4.
Ciprofloxacin (MIC = 1 μg/ml) versus S. pneumoniae SVI.
FIG. 5.
FIG. 5.
PD 0305970 (MIC = 0.008 μg/ml) versus S. pyogenes C203.
FIG. 6.
FIG. 6.
Ciprofloxacin (MIC = 2 μg/ml) versus S. pyogenes C203.
See this image and copyright information in PMC

References

    1. Bassetti, M., G. Melica, A. Di Biagio, E. Righi, R. Rosso, and D. Bassetti. 2004. New antibiotics for treatment of serious infections due to antibiotic-resistant gram-positive cocci. Rev. Med. Microbiol. 15:109-117.
    1. Cohen, M. A., M. D. Huband, S. L. Yoder, J. W. Gage, and G. E. Roland. 1998. Bacterial eradication by clinafloxacin, CI-990, and ciprofloxacin employing MBC test, in-vitro time-kill and in vivo time-kill studies. J. Antimicrob. Chemother. 41:605-614. - PubMed
    1. Cohen, M. A., S. L. Yoder, M. D. Huband, G. E. Roland, and C. L. Courtney. 1995. In vitro and in vivo activities of clinafloxacin, CI-990 (PD 131112), and PD 138312 versus enterococci. Antimicrob. Agents Chemother. 39:2123-2127. - PMC - PubMed
    1. Coleman, K. 2004. Recent advances in the treatment of gram-positive infections. Drug Discov. Today 1:455-460.
    1. Edelstein, P. H., M. A. C. Edelstein, J. Weidenfeld, and M. B. Dorr. 1990. In vitro activity of sparfloxacin (CI-978; AT-4140) for clinical Legionella isolates, pharmacokinetics in guinea pigs, and use to treat guinea pigs with L. pneumophila pneumonia. Antimicrob. Agents Chemother. 34:2122-2127. - PMC - PubMed

MeSH terms

Substances

LinkOut - more resources